Key result
Individualized renin-guided treatment shows promise for improving blood pressure control, with a proof-of-concept study demonstrating a 29 mm Hg reduction in mean systolic blood pressure.
Why the study?
Does individualized renin-guided treatment improve blood pressure control in patients with hypertension compared to standard empirical therapy?
Does individualized renin-guided treatment improve blood pressure control in patients with hypertension compared to standard empirical therapy?
Answers are grounded in this paper and cite their sources.
Individualized, renin-guided treatment of hypertension may offer a more rational and cost-efficient approach to achieving blood pressure control compared to current empirical algorithms.
Centuries ago, fever was considered a single condition or disease and it was treated by a single form of intervention, blood-letting.1 Later, we learned that fever has multiple causes that require very different interventions. Today, we treat hypertension in a similar way. Treatment guidelines and clinical practice make no real distinction between the different pathophysiological types of hypertension. The mantra—choose any of the large number of antihypertensive agents representing 10 different drug classes with different mechanisms of action and if the first choice does not work, add a second, a third, or a fourth drug type. This approach leads to an overutilization of drugs per patient and has been associated with poor outcomes. The excessive costs, medical and financial, are borne by patients and society. Sealey and Laragh2 have over many years provided an understanding of how hypertension really has multiple pathophysiologies that responds selectively or fails to respond to different drug treatment modalities. Thus, the time has come to examine ways to make treatment of hypertension more rationale and, thereby, more cost-efficient. There is growing evidence that better blood pressure control can be achieved without increasing the number of agents.3 In fact, one would ultimately expect a lower number of drugs per patient. The solution lies in the selection of the right initial drug for each patient. An added bonus to society with this approach is that it could in all cases be accomplished using less expensive generic agents. There are several objectives: First, decisions regarding treatment of a hypertensive person should be individualized. The “any size fits all” approach should have no place in hypertension treatment today. Second, more sensible algorithms for individual treatment approaches should be developed and tested. From a public health viewpoint, this is more important than developing new antihypertensive agents. Third, the overall goal should be to achieve much better blood pressure control in the population. This is likely to be accomplished by more rationale use of the currently available classes of drugs. Types of hypertension Pathophysiologically, there appears to be four major types of hypertension that require different initial drug treatment: Low-renin hypertension represents approximately one-third of all hypertensives, and this type usually responds very favorably to sodium volume-depleting natriuretic drugs (e.g., thiazide diuretics or spironolactone). Medium-/high-renin hypertension (responding to anti-renin system drugs) represents more than a third of all hypertensives. The effective drugs are ACE inhibitors, angiotensin receptor blockers, and the new direct renin inhibitors (e.g., aliskiren) that lower elevated blood pressure by blocking the plasma renin activity (PRA). “Resistant” hypertension by definition4 has elevated blood pressure that is uncontrolled on three or more drugs. Determination of PRA while taking these drugs can be helpful in selecting add-on or substitute drug types3 by indicating whether the failure of blood pressure control is due to (i) sodium-volume excess (low PRA), (ii) insufficiently blocked renin levels (high PRA), or (iii) a combination of both (medium PRA). Calcium channel blockers have a natriuretic role for the treatment of the low-renin form and, by suppressing renin secretion, β-blockers have a specific role in the treatment of high renin-resistant hypertension. Secondary hypertension includes renovascular and endocrine conditions such as primary aldosteronism and Cushing's disease that often require specific surgical or medical treatments directed at their underlying etiology. Uncritical use of antihypertensive agents for secondary hypertension may mask the underlying condition, thereby delaying proper treatments. This proposed categorization of hypertension based on seminal work by Laragh and Sealey could in the future form the foundation for individualized treatment of hypertensive persons, if documented to work in the clinical setting. Treatment implications The documentation in support of the proposed treatment algorithm is limited at this time. Recent data from ALLHAT5 are encouraging. Approximately 28% of participants randomized to chlorthalidone were controlled on monotherapy after 60 months. One would assume that they represent low-renin hypertension. Similarly, approximately 24% of those randomized to lisinopril were controlled on monotherapy after 60 months. The assumption is that they represent medium-/high-renin hypertension responding to antirenin system drugs. Thus, if these two groups are mutually exclusive, more than half of all hypertensive persons would be controlled on monotherapy. A proof-of-concept study3 of 39 patients with uncontrolled hypertension despite taking an average of three drugs showed very encouraging results. The renin-guided treatment normalized the uncontrolled blood pressures (reduction of mean systolic blood pressure of 29 mm Hg) without any increases in number of antihypertensive drugs per patient. The conclusion is that individualized renin-guided treatment has great promise. More research including randomized clinical trials are needed to determine the clinical implications of the proposed algorithm. The renin-guided treatment approach ought to be compared to a “JNC-7 approach” with mortality/morbidity outcomes. The clinical alternative—to continue treating hypertension the way we treated fever centuries ago—cannot be justified and is the reason for the failing report card.
No takes yet. Share an insight, caveat, or question.
C. D. Furberg (2008) conducted an editorial in Hypertension. Renin-guided treatment was evaluated. Individualized renin-guided treatment shows promise for improving blood pressure control, with a proof-of-concept study demonstrating a 29 mm Hg reduction in mean systolic blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: